-- Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) recorded a 70% decline in attributable profit in the first quarter of 2026 to 49 million yuan from 165.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.
Earnings per share slipped to 0.06 yuan from 0.19 yuan in the corresponding period of the previous fiscal year.
The medical laboratory company's revenue jumped 15% to 1.8 billion yuan from 1.56 billion yuan in the year-ago period.